CNXC Stock - Concentrix Corporation
Unlock GoAI Insights for CNXC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.62B | $7.11B | $6.32B | $5.59B | $4.72B |
| Gross Profit | $3.45B | $2.58B | $2.26B | $1.97B | $1.66B |
| Gross Margin | 35.9% | 36.2% | 35.7% | 35.3% | 35.2% |
| Operating Income | $596.39M | $661.33M | $640.19M | $572.40M | $308.76M |
| Net Income | $251.22M | $313.84M | $435.05M | $405.58M | $164.81M |
| Net Margin | 2.6% | 4.4% | 6.9% | 7.3% | 3.5% |
| EPS | $3.72 | $5.72 | $8.34 | $7.78 | $3.19 |
Concentrix Corporation provides technology-infused customer experience (CX) solutions worldwide. The company provides CX process optimization, technology innovation, front- and back-office automation, analytics, and business transformation services. It also offers customer lifecycle management; customer experience/user experience strategy and design; digital transformation; and voice of the customer and analytics solutions. The company's clients include consumer electronics, technology, e-commerce, and health insurance companies, as well as global IPOs, social brands, and banks. Concentrix Corporation was incorporated in 2009 and is based in Fremont, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 24th 2025 | Barrington Research | Reiterated | Outperform | $54← $70 |
| October 3rd 2024 | Robert W. Baird | Initiation | Outperform | $70 |
| August 28th 2024 | BofA Securities | Upgrade | Neutral | $85← $65 |
| March 27th 2024 | BofA Securities | Downgrade | Underperform | $60← $85 |
| September 6th 2023 | Redburn Atlantic | Initiation | Neutral | $70 |
| August 24th 2023 | Scotiabank | Initiation | Sector Outperform | $120 |
| June 29th 2023 | BofA Securities | Downgrade | Neutral | - |
| April 12th 2023 | Canaccord Genuity | Initiation | Buy | $150 |
Earnings History & Surprises
CNXCEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | — | — | — | — |
Q1 2026 | Jan 21, 2026 | $2.93 | — | — | — |
Q3 2025 | Sep 25, 2025 | $2.88 | $2.78 | -3.5% | ✗ MISS |
Q2 2025 | Jun 26, 2025 | $2.76 | $2.70 | -2.2% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $2.58 | $2.79 | +8.1% | ✓ BEAT |
Q1 2025 | Jan 15, 2025 | $3.00 | $3.26 | +8.7% | ✓ BEAT |
Q3 2024 | Sep 25, 2024 | $2.90 | $2.87 | -1.0% | ✗ MISS |
Q2 2024 | Jun 26, 2024 | $2.62 | $2.69 | +2.7% | ✓ BEAT |
Q1 2024 | Mar 26, 2024 | $2.58 | $2.57 | -0.4% | ✗ MISS |
Q1 2024 | Jan 24, 2024 | $3.09 | $3.36 | +8.7% | ✓ BEAT |
Q3 2023 | Sep 27, 2023 | $2.76 | $2.71 | -1.8% | ✗ MISS |
Q2 2023 | Jun 28, 2023 | $2.78 | $2.69 | -3.2% | ✗ MISS |
Q1 2023 | Mar 29, 2023 | $2.60 | $2.56 | -1.5% | ✗ MISS |
Q1 2023 | Jan 19, 2023 | $3.33 | $3.01 | -9.6% | ✗ MISS |
Q3 2022 | Sep 28, 2022 | $2.97 | $2.95 | -0.7% | ✗ MISS |
Q2 2022 | Jun 27, 2022 | $2.84 | $2.93 | +3.2% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $2.70 | $2.85 | +5.6% | ✓ BEAT |
Q1 2022 | Jan 18, 2022 | $2.71 | $2.99 | +10.3% | ✓ BEAT |
Q3 2021 | Sep 27, 2021 | $2.24 | $2.49 | +11.2% | ✓ BEAT |
Q2 2021 | Jun 23, 2021 | $2.26 | $2.37 | +4.9% | ✓ BEAT |
Latest News
Barrington Research Maintains Outperform on Concentrix, Maintains $62 Price Target
📈 PositiveBaird Maintains Outperform on Concentrix, Lowers Price Target to $62
➖ NeutralBarrington Research Maintains Outperform on Concentrix, Maintains $62 Price Target
📈 PositiveConcentrix shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results and issued Q4 adjusted EPS guidance below estimates. Also, the company cut its FY25 adjusted EPS guidance below estimates.
📉 NegativeConcentrix drops 21% as focus remains on margin recovery, tariff impact
📉 NegativeConcentrix shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results and issued Q4 adjusted EPS guidance below estimates. Also, the company cut its FY25 adjusted EPS guidance below estimates.
📉 NegativeConcentrix Lowers FY2025 Adj EPS Guidance from $11.53-$11.76 to $11.11-$11.23 vs $11.69 Est; Raises FY2025 Sales Guidance from $9.720B-$9.815B to $9.798B-$9.823B vs $9.772B Est
➖ NeutralConcentrix Sees Q4 Adj EPS $2.85-$2.96 vs $3.32 Est; Sees Sales $2.525B-$2.550B vs $2.525B Est
📉 NegativeConcentrix Q3 Adj. EPS $2.78 Misses $2.86 Estimate, Sales $2.483B Beat $2.458B Estimate
➖ NeutralBarrington Research Maintains Outperform on Concentrix, Maintains $62 Price Target
📈 PositiveBaird Maintains Outperform on Concentrix, Raises Price Target to $75
📈 PositiveReported Earlier, Concentrix Expands Presence In Vietnam With Acquisition Of SAI Digital To Deliver Innovation And Intelligent Experiences For Global Brands; Deal Terms Not Disclosed
📈 PositiveFrequently Asked Questions about CNXC
What is CNXC's current stock price?
What is the analyst price target for CNXC?
What sector is Concentrix Corporation in?
What is CNXC's market cap?
Does CNXC pay dividends?
Similar Stocks
Technology SectorExplore stocks similar to CNXC for comparison